6116-75-2

Usage

Uses

Used in Pharmaceutical Industry:
2,3-dimethyl-1,5,6,7-tetrahydro-4H-indol-4-one is used as a medication for the treatment of Parkinson's disease and restless legs syndrome. As a dopamine agonist, it stimulates dopamine receptors in the brain, thereby improving motor function and reducing the symptoms associated with Parkinson's disease. Additionally, it helps alleviate the uncomfortable sensations in the legs experienced by individuals with restless legs syndrome, making it an important compound in the management of these neurological conditions.

Upstream product

• 1609011-32-6 3-aminocyclohex-2-ene-1-one potassium salt 
• 814-75-5 3-bromo-butanone 
• 10412-98-3 5-oxohexanenitrile 
• 504-02-9 1,3-cylohexanedione 
• 57-71-6 2,3-Butanedione monoxime 
• 135636-66-7 butane-2,3-dione mono-oxime 

Downstream Products

• 7273-21-4 1,2,3-Trimethyl-4-oxo-4,5,6,7-tetrahydroindole 
• 1432509-88-0 methyl 4-((2,3-dimethyl-4-oxo-4,5,6,7-tetrahydroindol-1-yl)methyl)benzoate 
• 1432508-68-3 4-((2,3-dimethyl-4-oxo-4,5,6,7-tetrahydroindol-1-yl)methyl)-N-hydroxybenzamide 

Relevant academic research and scientific papers

Urea decomposition: Efficient synthesis of pyrroles using the deep eutectic solvent choline chloride/urea

A simple and efficient method is reported for the synthesis of pyrroles via condensation of a series of tricarbonyl compounds with ammonia, which was generated in situ from decomposition of the deep eutectic solvent choline chloride/urea.

Cyclization of cyanoethylated ketones as a route to 6-substituted indole derivatives

δ-Cyanoketones are quickly cyclized with KOtBu to 3-aminocyclohex-2-enone derivatives, which in turn will give substituted indoles when treated with oxalyl chloride. Thus, 3-amino-6,6-dimethylcyclohex-2-enone gave 3-chloro-6,6-dimethyl-2,5,6,7-tetrahydroindole-2,5-dione, whose structure was corroborated by X-ray crystallography, whereas the corresponding molecule without the blocking gem-dimethyl groups, 3-aminocyclohex-2-enone, gave via hydrogen shifts 6-chloro-3-hydroxyoxindole.

HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF

The present invention relates to a novel hydroxamate derivatives, more specifically, to novel hydroxamate derivatives having inhibitory activity against Histone Deacetylase (HDAC), isomers thereof, pharmaceutically acceptable salts thereof, hydrates or solvates thereof, use for preparing pharmaceutical compositions, pharmaceutical compositions comprising the same, treatment method using said composition, and a preparing method of novel hydroxamate derivatives. The novel selective hydroxamate derivatives having inhibitory activity against Histone Deacetylase (HDAC) compositions can be used for treatment of inflammatory disease, rheumatoid arthritis, or degenerative disease.

HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF

The present invention relates to a novel hydroxamate derivatives, more specifically, to novel hydroxamate derivatives having inhibitory activity against Histone Deacetylase (HDAC), isomers thereof, pharmaceutically acceptable salts thereof, hydrates or solvates thereof, use for preparing pharmaceutical compositions, pharmaceutical compositions comprising the same, treatment method using said composition, and a preparing method of novel hydroxamate derivatives. The novel selective hydroxamate derivatives having inhibitory activity against Histone Deacetylase (HDAC) compositions can be used for treatment of inflammatory disease, rheumatoid arthritis, or degenerative disease.

Discovery and synthesis of tetrahydroindolone derived semicarbazones as selective Kv1.5 blockers

A novel class of tetrahydroindolone-derived semicarbazones has been discovered as potent Kv1.5 blockers. In in vitro studies, several compounds exhibited very good potency for blockade of Kv1.5. Compound 8i showed good selectivity for blockade of Kv1.5 vs hERG and L-type calcium channels. In an anesthetized pig model, compounds 8i and 10c increased atrial ERP about 28%, 18%, respectively, in the right atrium without affecting ventricular ERP.

Nitrogen fixation: Synthesis of heterocycles using molecular nitrogen as a nitrogen source

Nitrogen fixation using transition metals is a fascinating process. We have already reported on the incorporation of molecular nitrogen into organic compounds using a titanium-nitrogen complex reported by Yamamoto. We developed a novel titanium-catalyzed nitrogenation procedure using TiCl4 in the presence of an excess amount of Li and TMSCl. In this reaction, a 1 atm pressure of nitrogen gas can be used and the reaction proceeds at room temperature. The procedure is very simple. A THF solution of TiCl4 or Ti(O iPr)4 (1 equiv.), Li (10 equiv.), and TMSCl (10 equiv.) was stirred under an atmosphere of nitrogen at room temperature overnight to give titanium-nitrogen complexes. Although the structures of the titanium-nitrogen complexes have not yet been determined, they would consist of N(TMS)3, X2TiN(TMS)2, and XTi=NTMS. Using this procedure, various heterocycles, such as indole, quinoline, pyrrole, pyrrolizine, and indolizine derivatives, could be synthesized from molecular nitrogen in good-to-moderate yields as a stoichiometric reaction based on a titanium complex by a one-pot reaction. Furthermore, monomorine I and pumiliotoxin C were synthesized from molecular nitrogen as a nitrogen source. This procedure was further extended for the syntheses of heterocycles using a catalytic amount of titanium complex; also, indole and pyrrole derivatives were obtained in high yields.